Dr. Terrence P. Cescon, MD
Hematology & Oncology (Hematology & Oncology Physician)
420 S 5th Ave, Bldg N Ground Reading Hospital Regional Cancer Ctr
West Reading, PA 19611
- Medicare participating
At a glance
- Medical school
- Hahnemann University College of Medicine (1988)
- Years since graduation
- 38
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 330
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1988Medical school: Hahnemann University College of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
PA license MD043684L
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Reading Hospital West Reading, PA
- Penn State Health St. Joseph Reading, PA
- Pottstown Hospital Pottstown, PA
Medical groups
- Reading Hospital (186 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 330
- Services billed
- 720
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 562 | 262 |
| Established patient office or other outpatient visit, 20-29 minutes | 162 | 147 |
| Established patient office or other outpatient visit, 40-54 minutes | 39 | 28 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 22 | 22 |
| New patient office or other outpatient visit, 45-59 minutes | 16 | 16 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Xarelto (rivaroxaban) Other prescribers in West Reading, PA | 93 |
| Dexamethasone Other prescribers in West Reading, PA | 92 |
| Hydroxyurea Other prescribers in West Reading, PA | 82 |
| Eliquis (apixaban) Other prescribers in West Reading, PA | 73 |
| Abiraterone Acetate | 72 |
| Ondansetron Hcl Other prescribers in West Reading, PA | 51 |
| Prednisone Other prescribers in West Reading, PA | 40 |
| Jakafi (ruxolitinib phosphate) | 31 |
| Imatinib Mesylate | 30 |
| Oxycodone Hcl Other prescribers in West Reading, PA | 28 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 1 payments worth $24.67 in total to this clinician.
| Pfizer Inc. | $24.67 |
|---|
| Food and Beverage | $24.67 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 9 industry-funded studies in 2025, from 6 companies. The companies reported $209,029 in research payments for these studies, mostly to the institutions running them.
- A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun)
Genentech, Inc. - Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC
Genentech, Inc. - A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)
Daiichi Sankyo Inc. · Active, not recruiting · NCT04622319 - Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC
Genentech, Inc. - A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous St…
Janssen Research & Development, LLC - Connect MM: The Multiple Myeloma Disease Registry. The purpose of the Connect MM Registry is to explore the natural history and real world management of patients with newly diagnosed symptomatic multiple myeloma (MM) …
E.r. Squibb & Sons, L.l.c. - A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
Karyopharm Therapeutics Inc. - Connect Myeloid: The Myelofibrosis (MF), Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry. The purpose of the Connect Myeloid disease registry is to provide unique insights into treatm…
Celgene Corporation - A Phase 3b, Randomized, Double-blind Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Monotherapy for Patients With Previously Untreated Advanced Renal Cell Carcinoma and Intermediate- or Poor-Risk Factors
E.r. Squibb & Sons, L.l.c.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.